subscribeSubscribe
price-trendAsk Us
Roche finally dumps phase 3 prostate cancer prospect

Roche finally dumps phase 3 prostate cancer prospect
Nick Paul Taylor FIERCE BIOTECH
03 Feb 2023
Share Share
Roche scraps 5 trials while Alzheimer`s, TIGIT plans still risky

Roche scraps 5 trials while Alzheimer`s, TIGIT plans still risky
James Waldron FIERCEBIOTECH
21 Jul 2022
Share Share
Roche chucks out phase 3 ipatasertib combo tests

Roche chucks out phase 3 ipatasertib combo tests
Ben Adams FIERCE BIOTECH
04 Feb 2021
Share Share
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga

ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
N. P. Taylor FIERCE BIOTECH
21 Sep 2020
Share Share
SU2C to support clinical trials in breast and prostate cancers

SU2C to support clinical trials in breast and prostate cancers
CLINEICALTRIALSARENA
18 Sep 2019
Share Share
Roche’s ipatasertib combo shows early promise in triple-negative breast cancer

Roche’s ipatasertib combo shows early promise in triple-negative breast cancer
Anna Smith PHARMA TIMES
03 Apr 2019
Share Share
Tecentriq combo shows promise in triple negative breast cancer

Tecentriq combo shows promise in triple negative breast cancer
PMLIVE
01 Apr 2019
Share Share